Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development at Global Scale

The partnership combines Abcam's expertise in antibody development with Genedata's proprietary data model and enterprise platform to enhance data connectivity, accelerate innovation, and help deliver high-quality reagents to researchers faster.

BASEL, Switzerland, Sept. 3, 2026 /PRNewswire/ -- Genedata, the leading provider of enterprise software for biopharmaceutical R&D, today announced an expanded collaboration with Abcam, a global provider of validated antibodies and assay solutions. By deploying Genedata Biologics^® across Abcam's global R&D organization, the two Danaher companies are working together to strengthen antibody development capabilities, unlock the value of scientific data, and accelerate AI-enabled innovation.

Genedata Biologics has been implemented at Abcam's headquarters in the UK and key sites in China and the US, creating a unified data foundation that connects global, cross-functional teams. The platform enables greater consistency, visibility, and collaboration throughout the antibody development process, helping Abcam scale operations while maintaining the high-quality standards researchers rely on.

"As researchers seek high-quality antibodies across a growing range of targets and applications, it is essential that we continue to scale and evolve our development capabilities to meet their needs," said Kaveh Kahen, PhD, President at Abcam. "By building on Genedata's world class platform we benefit from automation, connectivity, and flexibility needed to support our global R&D operations. Together, we have created a stronger foundation for data-driven innovation, enabling us to develop and deliver high-quality antibodies more efficiently and create greater value for customers."

Genedata Biologics provides a digital backbone for Abcam's antibody development pipeline, which delivers approximately 500 new antibodies to the market each year. The platform enables teams to manage complex workflows, track sample history, and capture and analyze antibody characterization data within a secure, structured environment. By bringing data, processes, and teams together, Abcam can work more efficiently and advance promising candidates faster, helping researchers gain access to the high-quality antibodies they need sooner.

"Abcam and Genedata share a commitment to applying data and technology to accelerate scientific innovation," said Othmar Pfannes, PhD, President of Genedata. "By combining Abcam's deep expertise in antibody development with the Genedata Biologics platform, we are creating an environment where Abcam's scientific teams can collaborate more effectively, generate actionable insights at scale, and build on a strong foundation for AI-powered discovery. The ultimate beneficiaries are researchers, who gain faster access to the validated reagents that support high-quality scientific outcomes."

About Genedata
Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharma R&D, transforms biopharma data into intelligence. Our innovative solutions combine deep science, technology, and AI domain knowledge. Leading biopharma organizations and cutting-edge biotechs partner with Genedata to digitalize and automate complex data workflows. Our advanced analytics and embedded AI enable data-driven decisions. From early discovery through development to the clinic, Genedata solutions drive innovation and maximize ROI, being trusted by customers worldwide for more than 25 years.

www.genedata.com
LinkedIn | YouTube

About Abcam
Abcam, a Danaher company, believes that the scientific community goes further, faster, when we go there together. We provide the research and clinical communities with expert scientific support, highly validated antibodies, assays, and other tools to address important targets in critical biological pathways. Today, we help 750,000 researchers in over 130 countries reach results faster in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges — helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

SOURCE Genedata